Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics

Journal of Psychiatric Research

Volumn 41, Issue 12, 2007, Pages 997-1004

  Zhang, Xiang Yang ^a,b,c   Tan, Yun Long ^b,c   Zhou, Dong Feng ^b   Cao, Lian Yuan ^c   Wu, Gui Ying ^a,c   Xu, Qi ^d   Shen, Yan ^d   Haile, Colin N ^a   Kosten, Therese A ^a   Kosten, Thomas R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^c BEIJING HUILONGGUAN HOSPITAL   (China)

^d INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Antipsychotic; BDNF; Schizophrenia; Serum; Sex difference; Weight gain

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; TRIFLUOPERAZINE;

ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHRONIC DISEASE; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; SERUM; WEIGHT GAIN;

EID: 34548172739     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2006.08.007     Document Type: Article

References (52)

1. Allison D.B., and Casey D.E. Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 62 Suppl. 7 (2001) 22-31
2. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156 (1999) 1686-1696
3. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389 (1997) 856-860
4. American Psychiatric Association. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Association, Washington DC
5. Angelucci F., Mathe A.A., and Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. Journal of Neuroscience Research 60 (2000) 783-794
6. Bai O., Chlan-Fourney J., Bowen R., Keegan D., and Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. Journal of Neuroscience Research 71 (2003) 127-131
7. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatrica Scandinavica 100 (1999) 3-16
8. Blackburn G.L. Weight gain and antipsychotic medication. Journal of Clinical Psychiatry 61 Suppl. 8 (2000) 36-41
9. Buckley P.F. Broad therapeutic uses of atypical antipsychotic medications. Biological Psychiatry 50 (2001) 912-924
10. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine 348 (2003) 1625-1638
11. Chlan-Fourney J., Ashe P., Nylen K., Juorio A.V., and Li X.M. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Research 954 (2002) 11-20
12. Correll C.U., and Malhotra A.K. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology 174 (2004) 477-489
13. Correll C.U., Leucht S., and Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. American Journal of Psychiatry 161 (2004) 414-425
14. Dietz W.H. Childhood weight affects adult morbidity and mortality. Journal of Nutrition 128 2 Suppl. (1998) 411S-414S
15. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Medicine 5 (2004) 11-25
16. Duric V., and McCarson K.E. Hippocampal neurokinin-1 receptor and brain-derived neurotrophic factor gene expression is decreased in rat models of pain and stress. Neuroscience 133 (2005) 999-1006
17. Fernandez-Moreno C., Pichel J.G., Chesnokova V., and De Pablo F. Increased leptin and white adipose tissue hypoplasia are sexually dimorphic in Lif null/Igf-I haploinsufficient mice. FEBS Letter 557 (2004) 64-68
18. Gielen A., Khademi M., Muhallab S., Olsson T., and Piehl F. Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients. Scandinavian Journal of Immunology 57 (2003) 493-497
19. Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, Lara DR. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. Journal of Psychiatric Research 2006; in press [Epub ahead of print].
20. Hellstrom L., Large V., Reynisdottir S., Wahrenberg H., and Arner P. The different effects of a Gln27Glu beta 2-adrenoceptor gene polymorphism on obesity in males and in females. Journal of Internal Medicine 245 (1999) 253-259
21. Herran A., Garcia-Unzueta M.T., Amado J.A., de La Maza M.T., Alvarez C., and Vazquez-Barquero J.L. Effects of long-term treatment with antipsychotics on serum leptin levels. British Journal of Psychiatry 179 (2001) 59-62
22. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350 (1991) 230-232
23. Jockers-Scherubl M.C., Danker-Hopfe H., Mahlberg R., Selig F., Rentzsch J., Schurer F., et al. Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neuroscience Letters 371 (2004) 79-83
24. Kane J.M. Extrapyramidal side effects are unacceptable. European Neuropsychopharmacology 11 Suppl. 4 (2001) 397-403
25. Karege F., Schwald M., and Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neuroscience Letter 328 3 (2002) 261-264
26. Kernie S.G., Liebl D.J., and Parada L.F. BDNF regulates eating behavior and locomotor activity in mice. EMBO Journal 19 (2000) 1290-1300
27. Lewin G.R., and Barde Y.A. Physiology of the neurotrophins. Annual Review of Neuroscience 19 (1996) 289-317
28. Lipska B.K., Khaing Z.Z., Weickert C.S., and Weinberger D.R. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. European Journal of Neuroscience 14 (2001) 135-144
29. Lommatzsch M., Zingler D., Schuhbaeck K., Schloetcke K., Zingler C., Schuff-Werner P., et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiology of Aging 26 (2005) 115-123
30. Lyons W.E., Mamounas L.A., Ricaurte G.A., Coppola V., Reid S.W., and Bora S.H. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 15239-15244
31. McIntyre R.S., Mancini D.A., and Basile V.S. Mechanisms of antipsychotic-induced weight gain. Journal of Clinical Psychiatry 62 Suppl. 23 (2001) 23-29
32. Nakazato M., Hashimoto K., Shimizu E., Kumakiri C., Koizumi H., and Okamura N. Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders. Biological Psychiatry 54 (2003) 485-490
33. Narita M., Aoki K., Takagi M., Yajima Y., and Suzuki T. Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 119 (2003) 767-775
34. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28 Suppl. 1 (2003) 83-96
35. Nawa H., Carnahan J., and Gall C. BDNF protein measured by a novel enzyme immunoassay in normal brain and after seizure: partial disagreement with mRNA levels. European Journal of Neuroscience 7 (1995) 1527-1535
36. Ono M., Itakura Y., Nonomura T., Nakagawa T., Nakayama C., Taiji M., et al. Intermittent administration of brain-derived neurotrophic factor ameliorates glucose metabolism in obese diabetic mice. Metabolism 49 (2000) 129-133
37. Pelleymounter M.A., Cullen M.J., and Wellman C.L. Characteristics of BDNF-induced weight loss. Experimental Neurology 131 (1995) 229-938
38. Perkins D.O. Adherence to antipsychotic medications. Journal of Clinical Psychiatry 60 Suppl. 21 (1999) 25-30
39. Pirildar S., Gonul A.S., Taneli F., and Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry 28 (2004) 709-713
40. Robinson T.N. Behavioural treatment of childhood and adolescent obesity. International Journal of Obesity and Related Metabolic Disorders 23 Suppl. 2 (1999) S52-S57
41. Russo-Neustadt A.A., and Chen M.J. Brain-derived neurotrophic factor and antidepressant activity. Current Pharmaceutical Design 11 (2005) 1495-1510
42. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., et al. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neuroscience Letters 351 (2003) 111-114
43. Sussman N. Review of atypical antipsychotics and weight gain. Journal of Clinical Psychiatry 62 Suppl. 23 (2001) 5-12
44. Sussman N. The implications of weight changes with antipsychotic treatment. Journal of Clinical Psychopharmacology 23 Suppl. 1 (2003) S21-S26
45. Tan Y.L., Zhou D.F., and Zhang X.Y. Decreased plasma brain derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophrenia Research 74 (2005) 263-270
46. Tan Y.L., Zhou D.F., Cao L.Y., Zou Y.Z., and Zhang X.Y. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neuroscience Letter 382 (2005) 27-32
47. Taylor D.M., and McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatrica Scandinavica 101 (2000) 416-432
48. Thoenen H. Neurotrophins and neuronal plasticity. Science 270 (1995) 593-598
49. Tonra J.R., Ono M., Liu X., Garcia K., Jackson C., and Yancopoulos G.D. Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice. Diabetes 48 (1999) 588-594
50. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Research 110 (2002) 249-257
51. Weiden P.J., Mackell J.A., and McDonnell D.D. Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research 66 (2004) 51-57
52. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldstein D., and Pashdag J. Novel antipsychotics: comparison of weight gain liabilities. Journal of Clinical Psychiatry 60 (1999) 358-363